Michael Thompson, PA
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,008 of the $1,608 with a category attached, or 62.7%. Pacira Pharmaceuticals Incorporated accounts for 76.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,226 and has fallen 97.5% since, to $31 in 2025.
Across 28 payments — averaging $57.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$1K
- Takeda Pharmaceuticals U.S.A., Inc.$144
- Intercept Pharmaceuticals, Inc.$131
- Johnson & Johnson$34
- Baxter Healthcare$31
- DJO, LLC$16
- plus $27 from 2 others
What the payments were for
- Travel & lodging$1,00863%
- Food & beverage$60037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 6 | $1,226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $144 |
| Intercept Pharmaceuticals, Inc. | 9 | $131 |
| Johnson & Johnson(2 entities) | 2 | $34 |
| Baxter Healthcare | 1 | $31 |
| DJO, LLC | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iovera$1,163
How this compares
$1,608 in reported general payments places this provider in the 75th percentile of 94 surgical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 78 | $649 |
| Meloxicam | 66 | $440 |
| Cephalexin | 14 | $60 |
| Amoxicillin | 17 | $16 |
Paid to pharmacies, not to this prescriber.
Other surgical in Tulsa
- Anne EdmondsTulsa$15K
- Isaac EdmondsTulsa$7K
- Camryn CorwinTulsa$5K
- Bryce WrightTulsa$4K
- Jamie TeeterTulsa$3K
- Shawna LiszewskiTulsa$3K
- Laura JuarezTulsa$3K
- Kristi KrebsTulsa$2K
- Crista HobbsTulsa$2K
- Jarret KellerTulsa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.